Ramucirumab

Phase 1Completed
0 watching 0 views this week๐Ÿ’ค Quiet
33
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pediatric Solid Tumor

Conditions

Pediatric Solid Tumor, Refractory Tumor, Recurrent Tumor, CNS Malignancies

Trial Timeline

Dec 11, 2015 โ†’ Jul 16, 2019

About Ramucirumab

Ramucirumab is a phase 1 stage product being developed by Eli Lilly for Pediatric Solid Tumor. The current trial status is completed. This product is registered under clinical trial identifier NCT02564198. Target conditions include Pediatric Solid Tumor, Refractory Tumor, Recurrent Tumor.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (9)

NCT IDPhaseStatus
NCT02065765Pre-clinicalCompleted
NCT04557384Phase 1Terminated
NCT03745430Phase 1/2Completed
NCT02564198Phase 1Completed
NCT02443883Phase 2Completed
NCT01983878Phase 2Completed
NCT01682135Phase 1Completed
NCT00721162Phase 2Completed
NCT00515697Phase 2Completed